Table 1.
Open in new tab

Clinical characteristics of the 132 adult DM patients

n = 132
Age at diagnosis of DMMean ± s.d.55 ± 15
Median (Q1–Q3)56 (44–66)
Sex (F/M)112 (84.8%)/20 (15.2%)
Duration of DM (years)Median (Q1–Q3)5 (1–10)
Necrosis/ulcerations (unknown =30)13 (12.7%)
Pharyngeal involvement (unknown =10)53 (43.4%)
Interstitial lung disease (unknown n = 5)14 (11.0%)
Presence of cancer72 (54.5%)
 Histology (unknown n = 4)
  Breast19 (27.9%)
  Ovaries15 (22.1%)
  Lungs8 (11.8%)
  ENT5 (7.4%)
  Lymphoma4 (5.9%)
  Colon3 (4.4%)
  Cervical2 (2.9%)
  Liver1 (1.5%)
  Leukaemia1 (1.5%)
  Myeloma1 (1.5%)
  Esophageal1 (1.5%)
  Peritoneum1 (1.5%)
  Lungs/Kidney1 (1.5%)
  Prostate1 (1.5%)
  Thymoma1 (1.5%)
  Uterus1 (1.5%)
  Vagina1 (1.5%)
  Bladder1 (1.5%)
  Bladder/Ovaries1 (1.5%)
 Timing DM/Cancer (uknown n = 10)
  Cancer before DM20 (32.3%)
  Cancer concomitant to DM (+/- 30 days)12 (19.3%)
  Cancer after DM30 (48.4%)
 Metastatic cancer (unknown n = 39)21 (63.6%)
 Cancer in remission at the latest news (unknown n = 19)15 (28.3%)
n = 132
Age at diagnosis of DMMean ± s.d.55 ± 15
Median (Q1–Q3)56 (44–66)
Sex (F/M)112 (84.8%)/20 (15.2%)
Duration of DM (years)Median (Q1–Q3)5 (1–10)
Necrosis/ulcerations (unknown =30)13 (12.7%)
Pharyngeal involvement (unknown =10)53 (43.4%)
Interstitial lung disease (unknown n = 5)14 (11.0%)
Presence of cancer72 (54.5%)
 Histology (unknown n = 4)
  Breast19 (27.9%)
  Ovaries15 (22.1%)
  Lungs8 (11.8%)
  ENT5 (7.4%)
  Lymphoma4 (5.9%)
  Colon3 (4.4%)
  Cervical2 (2.9%)
  Liver1 (1.5%)
  Leukaemia1 (1.5%)
  Myeloma1 (1.5%)
  Esophageal1 (1.5%)
  Peritoneum1 (1.5%)
  Lungs/Kidney1 (1.5%)
  Prostate1 (1.5%)
  Thymoma1 (1.5%)
  Uterus1 (1.5%)
  Vagina1 (1.5%)
  Bladder1 (1.5%)
  Bladder/Ovaries1 (1.5%)
 Timing DM/Cancer (uknown n = 10)
  Cancer before DM20 (32.3%)
  Cancer concomitant to DM (+/- 30 days)12 (19.3%)
  Cancer after DM30 (48.4%)
 Metastatic cancer (unknown n = 39)21 (63.6%)
 Cancer in remission at the latest news (unknown n = 19)15 (28.3%)
Table 1.
Open in new tab

Clinical characteristics of the 132 adult DM patients

n = 132
Age at diagnosis of DMMean ± s.d.55 ± 15
Median (Q1–Q3)56 (44–66)
Sex (F/M)112 (84.8%)/20 (15.2%)
Duration of DM (years)Median (Q1–Q3)5 (1–10)
Necrosis/ulcerations (unknown =30)13 (12.7%)
Pharyngeal involvement (unknown =10)53 (43.4%)
Interstitial lung disease (unknown n = 5)14 (11.0%)
Presence of cancer72 (54.5%)
 Histology (unknown n = 4)
  Breast19 (27.9%)
  Ovaries15 (22.1%)
  Lungs8 (11.8%)
  ENT5 (7.4%)
  Lymphoma4 (5.9%)
  Colon3 (4.4%)
  Cervical2 (2.9%)
  Liver1 (1.5%)
  Leukaemia1 (1.5%)
  Myeloma1 (1.5%)
  Esophageal1 (1.5%)
  Peritoneum1 (1.5%)
  Lungs/Kidney1 (1.5%)
  Prostate1 (1.5%)
  Thymoma1 (1.5%)
  Uterus1 (1.5%)
  Vagina1 (1.5%)
  Bladder1 (1.5%)
  Bladder/Ovaries1 (1.5%)
 Timing DM/Cancer (uknown n = 10)
  Cancer before DM20 (32.3%)
  Cancer concomitant to DM (+/- 30 days)12 (19.3%)
  Cancer after DM30 (48.4%)
 Metastatic cancer (unknown n = 39)21 (63.6%)
 Cancer in remission at the latest news (unknown n = 19)15 (28.3%)
n = 132
Age at diagnosis of DMMean ± s.d.55 ± 15
Median (Q1–Q3)56 (44–66)
Sex (F/M)112 (84.8%)/20 (15.2%)
Duration of DM (years)Median (Q1–Q3)5 (1–10)
Necrosis/ulcerations (unknown =30)13 (12.7%)
Pharyngeal involvement (unknown =10)53 (43.4%)
Interstitial lung disease (unknown n = 5)14 (11.0%)
Presence of cancer72 (54.5%)
 Histology (unknown n = 4)
  Breast19 (27.9%)
  Ovaries15 (22.1%)
  Lungs8 (11.8%)
  ENT5 (7.4%)
  Lymphoma4 (5.9%)
  Colon3 (4.4%)
  Cervical2 (2.9%)
  Liver1 (1.5%)
  Leukaemia1 (1.5%)
  Myeloma1 (1.5%)
  Esophageal1 (1.5%)
  Peritoneum1 (1.5%)
  Lungs/Kidney1 (1.5%)
  Prostate1 (1.5%)
  Thymoma1 (1.5%)
  Uterus1 (1.5%)
  Vagina1 (1.5%)
  Bladder1 (1.5%)
  Bladder/Ovaries1 (1.5%)
 Timing DM/Cancer (uknown n = 10)
  Cancer before DM20 (32.3%)
  Cancer concomitant to DM (+/- 30 days)12 (19.3%)
  Cancer after DM30 (48.4%)
 Metastatic cancer (unknown n = 39)21 (63.6%)
 Cancer in remission at the latest news (unknown n = 19)15 (28.3%)
Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close